Commitments and Contingencies (Details) - USD ($) |
6 Months Ended | |||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Dec. 31, 2025 |
May 13, 2024 |
Jun. 30, 2026 |
Jun. 30, 2025 |
May 12, 2026 |
|
| Commitments and Contingencies [Line Items] | ||||||
| Warrant agreement description | (a) the terms of the Public Warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or correcting any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the Public Warrants and the warrant agreement set forth in the prospectus, or defective provision (ii) removing or reducing the Company’s ability to redeem the Public Warrants and, if applicable, a corresponding amendment to the Company’s ability to redeem the Private Placement Warrants or (iii) adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Public Warrants under the warrant agreement in any material respect, (b) the terms of the warrants may be amended with the vote or written consent of at least 50% of the then outstanding Public Warrants and Private Placement Warrants, voting together as a single class, to allow for the warrants to be, or continue to be, as applicable, classified as equity in the Company’s financial statement and (c) all other modifications or amendments to the Company’s warrant agreement with respect to (i) the Public Warrants require the vote or written consent of holders of at least 50% of the then outstanding Public Warrants and (ii) the Private Placement Warrants require the vote or written consent of holders of at least 50% of the then outstanding Private Placement Warrants (including the vote or written consent of Cantor). Accordingly, the Company may amend the terms of the Public Warrants in a manner adverse to a holder of Public Warrants if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. Although the Company’s ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of ordinary shares purchasable upon exercise of a warrant. | |||||
| Aggregate deferred fee | $ 13,687,500 | $ 13,687,500 | ||||
| Deferred legal fee | 350,000 | $ 350,000 | $ 350,000 | |||
| Advisory services fees | ||||||
| Percentage of market trading price | 5.00% | |||||
| Non-redemption agreements expense | $ 217,807 | |||||
| Fair value per share | $ 10.89 | |||||
| Class A Ordinary Shares [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Units price per share (in Dollars per share) | $ 10 | $ 10 | ||||
| Sponsor [Member] | Class A Ordinary Shares [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Agreements of non-redemption to investors shares | 403,720 | |||||
| Fair value per share | $ 0.54 | $ 0.54 | ||||
| Non-Redemption Agreement [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Aggregate of shares subject to non-redemption | 8,074,387 | 8,074,387 | ||||
| Non-Redemption Agreement [Member] | Class A Ordinary Shares [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Aggregate of shares subject to non-redemption | 403,720 | 403,720 | ||||
| Non-Redemption Agreement [Member] | Sponsor [Member] | Class A Ordinary Shares [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Agreements of non-redemption to investors shares | 403,720 | |||||
| Over-Allotment Option [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Underwriter option period | 45 days | |||||
| Additional units (in Shares) | 3,750,000 | 3,750,000 | ||||
| Units price per share (in Dollars per share) | $ 10 | |||||
| Deferred fee per unit (in Dollars per share) | $ 0.65 | $ 0.65 | ||||
| Aggregate deferred fee | $ 2,437,500 | $ 2,437,500 | ||||
| IPO [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Additional units (in Shares) | 28,750,000 | 28,750,000 | ||||
| Cash underwriting discount (in Dollars per share) | $ 0.2 | |||||
| Cash underwriting discount | $ 5,000,000 | |||||
| Deferred fee per unit (in Dollars per share) | $ 0.45 | $ 0.45 | ||||
| Aggregate deferred fee | $ 11,250,000 | $ 11,250,000 | ||||
| IPO [Member] | Underwriting Agreement [Member] | ||||||
| Commitments and Contingencies [Line Items] | ||||||
| Additional units (in Shares) | 3,750,000 | |||||